MannKind (MNKD) is back in focus after presenting a broad package of Afrezza and FUROSCIX data at the American Diabetes ...
Stocktwits on MSN
MNKD stock eyes best month since 2022 ahead of FDA decision on pediatric diabetes treatment
MannKind posted Phase 3 trial results last October, comparing Afrezza in patients aged 4 to 17, with multiple daily insulin injections. ・MannKind will present additional Afrezza-related data at the ...
MannKind Corporation (NASDAQ:MNKD) is among the hidden penny stocks to invest in. On June 1, Wells Fargo lifted the price ...
MannKind (NASDAQ: MNKD) was a stock to avoid on the second-to-last trading day of the week. Investors eagerly sold out of the commercial-stage biotech's equity, as they clearly felt its latest ...
Transaction value based on SEC Form 4 weighted average purchase price ($6.01); post-transaction value based on Dec. 17, 2025 market close price ($5.97). MannKind Corporation is a biotechnology company ...
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. MannKind (MNKD) is a stock that can certainly grab the attention ...
Hosted on MSN
MannKind stock slips despite FDA clearing pediatric use of heart failure drug — what’s spooking investors?
The FDA expanded Furoscix use to certain pediatric patients. MannKind received five new U.S. patents supporting its ReadyFlow autoinjector, which is still under FDA review. The FDA is expected to ...
MannKind Corp. shares dropped nearly 15 percent on Tuesday after the cash-strapped biotech said that it plans to sell $50 million worth of stock and warrants in a public offering. The company also ...
Transaction value based on SEC Form 4 weighted average purchase price ($6.01); post-transaction value based on Dec. 17, 2025 market close price ($5.97). MannKind Corporation's key products include ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results